Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 1.484 EUR 0.54%
Market Cap: 97.6m EUR

Oryzon Genomics SA
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Oryzon Genomics SA
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Oryzon Genomics SA
MAD:ORY
Additional Paid In Capital
€92.4m
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Grifols SA
MAD:GRF
Additional Paid In Capital
€910.7m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Pharma Mar SA
MAD:PHM
Additional Paid In Capital
€59.9m
CAGR 3-Years
-6%
CAGR 5-Years
-3%
CAGR 10-Years
-16%
Biotechnology Assets SA
MAD:BST
Additional Paid In Capital
€99.2m
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
N/A

Oryzon Genomics SA
Glance View

Market Cap
93.4m EUR
Industry
Biotechnology

Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

ORY Intrinsic Value
1.402 EUR
Overvaluation 6%
Intrinsic Value
Price

See Also

What is Oryzon Genomics SA's Additional Paid In Capital?
Additional Paid In Capital
92.4m EUR

Based on the financial report for Dec 31, 2023, Oryzon Genomics SA's Additional Paid In Capital amounts to 92.4m EUR.

What is Oryzon Genomics SA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
9%

Over the last year, the Additional Paid In Capital growth was 16%. The average annual Additional Paid In Capital growth rates for Oryzon Genomics SA have been 8% over the past three years , 9% over the past five years .

Back to Top